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erythropoietin increases Myelination 
in Oligodendrocytes: gene 
expression Profiling reveals early 
induction of genes involved in lipid 
Transport and Metabolism
Georgina Gyetvai, Trisha Hughes, Florence Wedmore, Cieron Roe, Lamia Heikal,  
Pietro Ghezzi and Manuela Mengozzi*
Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, United Kingdom
Several studies have shown that erythropoietin (EPO) has neuroprotective or neurore-
parative actions on diseases of the nervous system and that improves oligodendrocyte 
(OL) differentiation and myelination in vivo and in vitro. This study aims at investigating 
the early molecular mechanisms for the pro-myelinating action of EPO at the gene 
expression level. For this purpose, we used a differentiating OL precursor cell line, rat 
central glia-4 cells. Cells were differentiated or not, and then treated with EPO for 1 or 
20 h. RNA was extracted and changes in the gene expression profile were assessed 
using microarray analysis. Experiments were performed in biological replicates of n = 4. 
Differentiation alone changed the expression of 11% of transcripts (2,663 out of 24,272), 
representing 2,436 genes, half of which were upregulated and half downregulated. 
At 20 h of treatment, EPO significantly affected the expression of 99 genes that were 
already regulated by differentiation and of 150 genes that were not influenced by differ-
entiation alone. Analysis of the transcripts most upregulated by EPO identified several 
genes involved in lipid transport (e.g., Cd36) and lipid metabolism (Ppargc1a/Pgc1alpha, 
Lpin1, Pnlip, Lpin2, Ppard, Plin2) along with Igf1 and Igf2, growth factors known for their 
pro-myelinating action. All these genes were only induced by EPO and not by differenti-
ation alone, except for Pnlip which was highly induced by differentiation and augmented 
by EPO. Results were validated by quantitative PCR. These findings suggest that EPO 
might increase remyelination by inducing insulin-like growth factors and increasing lipid 
metabolism.
Keywords: central glia-4, microarrays, cD36, Pnlip, igF-1, tissue-protective cytokines, repair, erK1/2
inTrODUcTiOn
Myelination is essential for the proper functioning of the central nervous system (CNS). 
Oligodendrocyte (OL) damage and remyelination failure cause progressive neurological disability in 
chronic demyelinating diseases, including multiple sclerosis (MS), and also play a role in the patho-
genesis of other neurological diseases, such as stroke, amyotrophic lateral sclerosis, and Alzheimer’s 
disease (1, 2).
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Myelination occurs in development and continues postnatally. OL 
progenitor cells (OPCs) are present in the adult CNS; upon OL injury, 
OPCs contribute to OL regeneration and remyelination. However, in 
demyelinating diseases endogenous remyelination is insufficient to 
re-establish motor and cognitive performance. Absence of remyeli-
nation is often due to the inability of OPCs to differentiate and mature 
to produce myelin. Therapeutic agents that can stimulate OPCs to 
differentiate and remyelinate axons could improve neurological 
functions and clinical outcome in many pathologies (3, 4).
Erythropoietin (EPO) has neuroprotective and neurore-
parative actions in many models of disease and injury of the 
nervous system (5); although recent evidence points to the role 
of the EPOR/CD131 heteromeric receptor in mediating EPO 
reparative functions (6), EPO can act also through the classical 
EPOR homodimer (7, 8). EPO induces neurogenesis and oligo-
dendrogenesis (9, 10); it preserves myelin and increases myelin 
basic protein (MBP) expression in experimental models of demy-
elination and in white matter injury (11, 12). EPO increases the 
differentiation of OL precursors and the maturation of late stage 
OLs in vitro and in vivo (8, 10, 13).
Understanding the mechanism by which EPO acts on OLs 
might help identify therapeutic targets for remyelination.
The mechanisms that mediate differentiation and matura-
tion of OLs are not completely understood. Studies have been 
hampered by the limited availability of high numbers of primary 
OPCs. Central Glia-4 (CG4) cells, an OL precursor permanent 
cell line derived from rat brain, can remyelinate axons in  vivo 
(14). In vitro, in the absence of mitogens and serum, CG4 cells 
differentiate into MBP-expressing OLs within 48 h; then myelin 
oligodendrocyte glycoprotein (MOG), a marker of myelin depo-
sition, is produced (15, 16). Therefore, CG4 are considered a good 
in vitro model of CNS myelination (17). We recently found that 
EPO increases myelin gene expression in differentiating CG4 
cells; EPO promoted differentiation of OPCs into MBP- and 
MOG-positive OLs (8).
The aim of this study was to investigate the mechanisms medi-
ating the pro-myelinating effects of EPO on CG4 cells. To this 
purpose, we analyzed the changes in the gene expression profile 
induced by EPO in differentiating cells at two time points, 1 and 
20 h after EPO treatment, focusing on the transcriptional changes 
occurring during the OPC to OL transition. The results highlight 
an inducing effect of EPO on genes previously known to play a 
role in myelination, such as insulin-like growth factor-1 (Igf1), 
Igf2, protein tyrosine phosphatase receptor type E (Ptpre), as well 
as genes involved in lipid transport and metabolism, including 
fatty acid translocase (Fat/Cd36), peroxisome proliferator-
activated receptor-gamma coactivator (Ppargc1a/Pgc1alpha), and 
pancreatic lipase (Pnlip) (18–24).
MaTerials anD MeThODs
cell culture
The wild-type CG4 cell line, a rat OL precursor cell line originally 
obtained from primary cultures of bipotential oligodendrocyte-
type-2-astrocytes (O-2A), was kindly donated by Huseyin 
Mehmet, Imperial College, London. CG4 cells, as primary 
O-2A cells, can differentiate into mature OLs by withdrawal of 
growth factors (bFGF and PDGF) and of B104 mitogens, or into 
astrocytes by addition of 20% fetal calf serum. Undifferentiated 
cells are bipolar; after 2 days of differentiation they acquire about 
90% of multipolar morphology. Differentiated CG4 cells express 
myelin proteins, including MBP and MOG (15–17).
CG4 cells overexpressing EPOR (CG4-EPOR) were generated 
as reported in our previous study (8). Briefly, CG4-EPOR cells 
were obtained by transduction of CG4 cells with the mouse EPOR 
gene in a constitutive lentiviral vector, modified to include the 
V5 epitope, the mouse encephalomyocarditis internal ribosome 
entry site (IRES) and the enhanced green fluorescent protein 
(EGFP) reporter. The expression of recombinant V5-tagged 
EPOR in transduced CG4 cells was verified by measuring by flow 
cytometry the EGFP reporter expression, and by immunoblotting 
with the anti-V5-tag mouse monoclonal antibody (Invitrogen), 
as described (8, 25).
CG4-EPOR cells were seeded in poly-l-ornithine-coated 
6-well plates (320,000 cells in 4  ml GM per well). They were 
maintained at the precursor stage by culture in growth medium 
(GM), consisting of Dulbecco’s modified Eagle medium 
(DMEM) (Sigma-Aldrich) supplemented with biotin (10 ng/ml), 
bFGF (5  ng/ml), PDGF (1  ng/ml), N1 supplement (all from 
Sigma-Aldrich), and 30% B104-conditioned medium, obtained 
as previously reported (8). After overnight culture, the cells were 
induced to differentiate into OLs by switching to differentiation 
medium (DM), consisting of DMEM-F12 (Invitrogen) sup-
plemented with progesterone (3 ng/ml), putrescine (5 µg/ml), 
sodium selenite (4  ng/ml), insulin (12.5  µg/ml), transferrin 
(50 µg/ml), biotin (10 ng/ml), thyroxine (0.4 µg/ml), and glucose 
(3 g/l) (all from Sigma-Aldrich), as reported (8). After 3 h, some 
of the cells were treated with recombinant human erythropoi-
etin (rhEPO; Creative Dynamics) at 10 ng/ml and cultured for 
1 or 20 h prior to RNA extraction. There is extensive biological 
cross-reactivity between human EPO and the EPOs of other 
mammals. Human EPO is approximately 80% homologous to 
rodent EPO, and it has been shown to be biologically active 
in rodents for erythropoietic and neurotrophic functions (26, 
27). Undifferentiated cells were seeded as above and cultured 
in GM without switching to DM for the whole length of the 
experiment.
To measure ERK1/2 phosphorylation by western blot, cells 
were plated in poly-ornithine coated 24 well plates at 200,000/well 
in GM for 24 h, then switched to DM and incubated overnight 
to starve them of growth factors present in GM. Cells were then 
preincubated with PD184352 (Cell Signaling, #12147) or DMSO 
for 1  h, then treated with or without EPO at 10  ng/ml for the 
indicated times. PD184352 was dissolved in DMSO at 25 mg/ml 
and then diluted in DM at the indicated concentrations.
rna extraction
Each sample was lysed with 1  ml QIAzol (QIAGEN). Total 
RNA was extracted by using the miRNeasy system and protocol 
(QIAGEN). RNA purity and integrity were determined using a 
NanoDrop ND-1000 (NanoDrop Technologies) and an Agilent 
2100 Bioanalyzer (Agilent Technologies). All samples had a 
A260/A280 ratio >1.8 and RNA Integrity Number >9.
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Microarrays
All experimental conditions were performed in quadruplicate; 
undifferentiated cells were cultured in quadruplicate but only 
three random samples were used for microarray analysis and all 
of the four samples for quantitative PCR (qPCR) validation. In 
total, 19 arrays were completed: 3 undifferentiated (und) and 16 
differentiated: 4 differentiated (ctr) and 4 differentiated + EPO 
(EPO) at each time point (4 and 23 h of differentiation; 1 and 20 h 
after EPO treatment, respectively).
RNA was amplified, labeled, and hybridized onto Single Color 
SurePrint G3 Rat GE 8 × 60K Microarrays (AMADID:028279; 
Agilent) at Oxford Gene Technology, Oxford, UK. Following 
hybridization, the arrays were scanned to derive the array images. 
Feature extraction software v10.7.3.1 was used to generate the 
array data from the images.
Microarray Data analysis
Raw data in standard format from the microarray experiment 
have been deposited in the Gene Expression Omnibus (GEO) 
database of NCBI (28) and are accessible through GEO Series 
accession number GSE84687.1 Raw data were normalized 
and analyzed using GeneSpring (Agilent) and Excel software. 
Transcript expression levels between the experimental groups 
were compared by Student’s t-test done on the log2 of the 
gProcessed Signal, obtaining uncorrected p-values. Subsequent 
multiple comparison corrections were performed using the 
Benjamini-Hochberg False Discovery Rate procedure, obtaining 
adjusted p-values. Fold change in the expression was calculated 
as the ratio between the average of the gProcessed Signals of the 
various groups and expressed as log2. Differences in expression 
with an adjusted p-value < 0.05 and an absolute fold change ≥ 1.5 
(log2 fold change ≥ 0.58) were considered statistically significant. 
Functional annotation and biological term enrichment was done 
using the Database for Annotation, Visualization, and Integrated 
Discovery (DAVID)2 (29). DAVID calculates a modified Fisher’s 
exact p-value to demonstrate enrichment. Categories with 
p-value < 0.05 were considered significantly enriched.
Microarray Data Validation by rT-qPcr
Reverse transcription (RT) and real-time qPCR were carried 
out as reported (30) on total RNA from quadruplicate samples, 
using TaqMan® gene expression assays (Applied Biosystems/Life 
Technologies) and Brilliant III qPCR master mix (Stratagene/
Agilent Technologies). Gene expression was quantified using 
the ΔΔCt method, according to Applied Biosystems’ guidelines. 
Results were normalized to HPRT1 expression (reference gene) 
and expressed as log2 of the relative expression (ratio) vs one of 
the control samples (as indicated), chosen as the calibrator.
Western Blot analysis
Cells were lysed in RIPA buffer (Thermo Fisher Scientific) and 
total cellular extracts were incubated on ice for 30 min and then 
cleared by centrifugation (15,000 g for 20 min at 4°C). Protein 
1 http://www.ncbi.nlm.nih.gov/geo.
2 https://david-d.ncifcrf.gov.
concentration was measured with the BCA kit (Pierce) and 30 µg 
of cellular proteins were analyzed by 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred to a nitrocel-
lulose membrane (Millipore) by electroblotting. Membranes 
were blocked for 1  h with 5% bovine serum albumin (BSA, 
Sigma-Aldrich) in TBS and then probed with rabbit polyclonal 
anti-phospho-ERK1/2 (Cell Signaling, #9101) followed by detec-
tion with goat-anti-rabbit-IgG-horseradish peroxidase conjugate 
(Sigma-Aldrich, #A0545), all in 5% BSA in TBS with 0.1% Tween 
20 (Sigma-Aldrich). Membranes were then stripped with Re-Blot 
Plus Strong Solution (Millipore) and then blocked and reprobed 
with rabbit polyclonal anti-ERK1/2 (Cell Signaling, #9102). 
Protein bands were visualized using ECL detection reagent (GE 
Healthcare) and exposing the membranes to autoradiography 
films (Hyperfilms, GE Healthcare).
resUlTs
experimental Design
Undifferentiated CG4 cells cultured for 1  day in GM were 
switched to DM and treated with EPO (10 ng/ml) after 3 h; gene 
expression analysis was performed 1 and 20 h upon EPO stimula-
tion (at 4 and 23 h of differentiation, respectively). The dose of 
EPO was chosen based on dose–response experiments published 
in our previous study; since in these cells EPO dose-dependently 
induced MOG and MBP expression with maximal induction at 
8 ng/ml and no further increase at 80 and 400 ng/ml, the dose 
of 10  ng/ml was used throughout this study (8). EPO-treated 
were compared with untreated differentiating cells; the effect of 
differentiation was investigated by comparison with undifferen-
tiated cells cultured for 1 day in GM in the same experimental 
conditions. Genes differentially expressed were identified by set-
ting a cutoff fold change (FC) of 1.5 (log2 FC = 0.58) and cutoff 
p-value  <  0.05 after applying the Benjamini–Hochberg (BH) 
correction for multiple tests.
genes regulated by Differentiation  
and ePO
At 20 h, culture in DM changed the expression of 2,663 out of 
24,272 transcripts. Five genes represented by duplicate probes 
changed in opposite directions were excluded from the analysis; 
when genes were represented by duplicate or triplicates probes 
consistently changed in the same direction, only the most 
significantly changed one was included, obtaining 2,436 genes, 
of which 99 were further changed in the same direction by 
EPO; 21,609 transcripts were unaffected by differentiation, 
of which 174, representing 150 genes, were changed by EPO 
(Figure 1). The relative expression changes of all genes affected 
by differentiation (2,436; 1,164 upregulated and 1,272 down-
regulated; Figure 1) and/or by EPO (278; 177 upregulated and 
101 downregulated; Figure 1) and details about the redundant 
probes removed are reported in Files S1–S3 in Supplementary 
Material.
On the other hand, 1 h of EPO treatment had little effect on 
the gene expression profile. Culture for 4 h in DM affected 931 
transcripts out of 24,272; after removing one gene represented by 
FigUre 1 | Transcripts regulated by erythropoietin (EPO) at 20 h in differentiating central glia-4 (CG4) cells. Cells cultured for 1 day in growth medium (GM) were 
switched to differentiation medium (DM); after 3 h, EPO was added and cells were incubated for further 20 h. (a) Transcripts regulated by differentiation were 
selected by comparing differentiating (23 h culture with DM) vs undifferentiated cells and transcripts regulated by EPO by comparing EPO-treated (20 h) vs untreated 
differentiating cells. Cutoff for selection was a fold change of 1.5 and BH adj. p-value < 0.05. The number of transcripts resulting from filtering is indicated and color 
coded (red, increased; green, decreased). (B) Venn diagrams representing the overlap between transcripts regulated by differentiation and downregulated (left 
diagrams) or upregulated (right diagrams) by EPO, selected as described in (a).
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duplicate probes changed in opposite directions, and redundant 
probes, 878 genes were obtained; of these, 461 were upregulated 
and 417 downregulated. The addition of EPO for the last hour 
increased the expression of only six transcripts, corresponding 
to five genes (Egr1, H19, Fos, Arl4a, Irx2), of which three (Egr1, 
Fos, and Irx2) had been decreased, and therefore changed in the 
opposite direction, by previous culture in DM; the remaining 
two, H19 and Arl4a, had been unaffected by differentiation. The 
experimental design flowchart at 1  h is shown in Figure S1 in 
Supplementary Material and the whole list of the genes affected 
by differentiation and/or by EPO at 1 h, with details about the 
removed probes, is provided in Files S4 and S5 in Supplementary 
Material.
To understand the general function of the genes up- or 
downregulated in differentiating cells at 20 h, we used DAVID 
to identify the overrepresented GO categories with biological 
process (BP) designation (GO:BP).
Strongly proliferating OPCs need to exit the cell cycle to start 
differentiating and producing myelin proteins (31). Therefore, 
unsurprisingly, the top overrepresented GO:BP categories 
identified by DAVID analysis of the 1,272 genes downregulated 
by differentiation (full list, File S1 in Supplementary Material) 
included “cell division” and “mitotic nuclear division.” Thus, dif-
ferentiation inhibited the expression of many genes driving cell 
proliferation; this confirms previous studies in CG4 cells (15, 32) 
and in primary OLs (33, 34).
Erythropoietin further downregulated the expression of 56 
genes already decreased by differentiation, and of 37 of the unaf-
fected ones (Figure 1; File S3 in Supplementary Material); the top 
enriched GO:BP terms in both groups of genes included “DNA 
TaBle 1 | Top enriched functional GO:BP categories in transcripts upregulated by differentiation or specifically upregulated by EPO at 20 h.
gO:BP category Fold 
enrichment
gene symbols p-value
Upregulated by differentiation (1,164)
Nervous system development 2.7 GRIP1, ERBB2, GPM6B, TNR, SMIM3, SH2B2, NDRG2, BHLHE40, CABLES1, SIM2, INA, MAG, 
NR4A2, DPYSL3, CSRP1, PTPRO, GAS7, PURA, SLITRK1, NTRK1, VEGFA, OPHN1, IFT88, 
GFRA2, KCTD11
2.2E−05
Cell adhesion 2.2 CHE, OPCML, BCAR1, NINJ2, NEO1, CD9, IGSF11, LGALS3BP, PTK2, SORBS2, TNR, ACAN, 
EMB, NEGR1, MLLT4, SPON1, MAG, ICAM5, PODXL, CDHR2, ITGA4, CERCAM, SSPO, FARP2, 
VWF, LSAMP, CX3CR1, RELN, PDZD2, NTM
8.2E−05
Fatty acid beta-oxidation 4.8 CPT1C, ACAA2, ACADSB, CPT2, EHHADH, ABCD2, DECR1, HSD17B4, HADH, ACAA1B 1.7E−04
Glycolytic process 4.8 ALDOA, ALDOART2, TPI1, PFKL, ALDOC, ENO2, PFKM, PGK1, DHTKD1 4.3E−04
Upregulated by erythropoietin (ePO) and unchanged by differentiation alone (113)
Response to organic cyclic compound 6.2 PRKCQ, FOS, CYP1B1, PLIN2, CD44, CTGF, IGF-1, IGF-2, TIMP3, PPARGC1A 3.1E−05
Response to activity 11.2 PPARD, CD36, IGF-1, FGF21, ZEB1, PPARGC1A 1.9E−04
Response to nutrient levels 10.1 IGF-1, IGF-2, FGF21, ZEB1, PPARGC1A, H19 3.1E−04
Positive regulation of ERK1 and ERK2 
cascade
6.8 SPRY2, CD36, CD44, CTGF, ANGPT1, FGF21, HTR2C 5.5E−04
DAVID Functional Annotation Chart Analysis showing the four top overrepresented GO:BP categories among the transcripts upregulated by differentiation or specifically upregulated 
by EPO and unchanged by differentiation alone. The fold enrichment and the significance of the enrichment (a modified Fisher’s exact p-value calculated by DAVID) is reported. In 
bold the genes further upregulated by EPO (Table S2 in Supplementary Material).
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replication”; only 8 transcripts were downregulated by EPO but 
upregulated by differentiation, and a PubMed search did not 
highlight any link with OLs or myelination. Therefore, analysis 
of the EPO-downregulated genes revealed a strong inhibitory 
action of EPO on a network of genes involved in cell proliferation, 
some of which were already affected by differentiation; however, 
it did not suggest any other mechanism that might be triggered 
by EPO through gene downregulation. The DAVID analysis of 
the genes downregulated by differentiation and/or by EPO is 
reported in File S6 in Supplementary Material.
Among the 1,164 genes upregulated by differentiation alone 
(full list, File S1 in Supplementary Material), the top enriched 
GO:BP categories were “nervous system development” (n = 25), 
which included genes involved in myelination, such as Mag and 
Erbb2 (35), “cell adhesion” (n = 30), including genes previously 
found upregulated in differentiating OLs, such as Cd9, Neo1, 
Ninj2, Opcml, Tnr (36), “fatty acid beta-oxidation” (n = 10), and 
“glycolysis” (n = 9), both required to provide intermediates for 
myelin synthesis and energy to support the myelination process 
(Table 1) (37, 38). EPO further upregulated 43 of the transcripts 
already increased by differentiation alone (Figure  1; File S2 in 
Supplementary Material), among which DAVID analysis did not 
highlight any enriched GO:BP category. However, by manual 
analysis we identified two myelin genes [Mag and Pmp2, a periph-
eral myelin protein which is also present in the CNS (39)], one 
gene belonging to the GO:BP “nervous system development” 
(Mag) and three genes to “cell adhesion” (Cdhr2, Mag, Ntm) but 
none to “fatty acid beta-oxidation” or “glycolysis.” Twenty-one 
transcripts were upregulated by EPO but downregulated by dif-
ferentiation, including low density lipoprotein receptor (Ldlr), 
which is expressed in mature OLs (40) and myelin transcription 
factor 1 (Myt1), whose multiple functions on proliferation and 
differentiation of OLs, likely dependent on interacting molecules, 
have not been fully characterized (33).
genes specifically induced by ePO
We then looked at the transcripts specifically increased by EPO 
but unchanged by differentiation alone (113; Figure 1). The 15 
most induced genes in this group are reported in Table 2 (full 
list, File S2 in Supplementary Material). Some of these genes have 
been described to play a role in myelination, including Igf1 and 
Igf2 (21), and Ptpre, a protein tyrosine phospatase whose knock-
outs have defects in myelination (19). Interestingly, PTPRE also 
inhibits ERK activation (41). DAVID analysis identified enrich-
ment of generic GO:BP terms including “response to organic 
cyclic compounds” (n  =  10), “response to activity” (n  =  6), 
“response to nutrient levels” (n = 6), and positive regulation of 
ERK1 and ERK2 cascade (n = 7) (Table 1).
ePO increases the expression of Cd36 
and of genes involved in lipid Metabolism
We noticed, in the list in Table 2, a strong effect of EPO (about 
50-fold induction) on Cd36, which mediates long-chain fatty acid 
uptake and metabolism (22, 42).
We, therefore, searched manually for other genes involved 
in lipid transport and metabolism among all the transcripts 
increased by EPO, including those also changed by differen-
tiation alone (177; Figure 1; File S2 in Supplementary Material). 
We specifically searched for genes annotated with GO:0006629 
“lipid metabolic process,” GO:0006631 “fatty acid metabolism,” 
GO:0006635 “fatty acid beta-oxidation,” GO:0019395 “fatty acid 
oxidation,” and GO:0015909 “long-chain fatty acid transport.” 
Other than Cd36, our search identified Ppargc1a/Pgc1alpha, 
TaBle 3 | Transcripts involved in lipid transport and metabolism induced by erythropoietin (EPO) at 20 h in differentiating cells.
Probename genesymbol genbankaccession ePO vs differentiation
log2 Fc p-value Bh adj. p-value
A_64_P054808 Cd36 NM_031561 6.98 5.4E−08 1.5E−04
A_44_P305482 Ppargc1a NM_031347 1.48 1.7E−04 1.6E−02
A_44_P191309 Lpin1 XM_006239912 1.00 2.9E−05 6.0E−03
A_44_P254984 Pnlipa NM_013161 0.92 2.1E−05 5.2E−03
A_44_P1045748 Lpin2 NM_001108236 0.71 5.8E−04 2.9E−02
A_42_P458711 Ppard NM_013141 0.67 1.3E−04 1.4E−02
A_42_P839964 Plin2 NM_001007144 0.67 1.3E−04 1.4E−02
All the genes increased by EPO at 20 h identified with GO “lipid metabolic process” (GO:6629), “fatty acid metabolism” (GO:6631), “fatty acid oxidation” (GO:19395), “fatty acid 
beta-oxidation” (GO:6635), “long-chain fatty acid transport” (GO:15909) are listed. Cutoff for significance: fold change (FC) > 1.5 (log2 FC > 0.58) and BH adj. p-value < 0.05 in 
EPO-treated differentiated cells vs differentiation alone.
aIncreased also by differentiation alone (log2 FC 1.9, p-value 9.7E−05, BH adj. p-value 3.7E−03 when comparing differentiated vs undifferentiated cells).
TaBle 2 | Top 15 transcripts upregulated by erythropoietin (EPO) in differentiating cells at 20 h.
Probename genesymbol genbankaccession ePO vs differentiation
log2 Fc p-value Bh adj. p-value
A_44_P342289 H19 NR_027324 12.53 2.4E−07 3.2E−04
A_64_P054808 Cd36 NM_031561 6.98 5.4E−08 1.5E−04
A_44_P792784 Htr2c NM_012765 5.14 4.2E−09 5.1E−05
A_64_P128810 RGD1565355 NM_001109218 5.11 2.7E−08 9.3E−05
A_64_P069419 Tnfrsf11a NM_001271235 4.37 4.9E−09 4.0E−05
A_64_P137130 Ptpre NM_053767 4.01 3.3E−07 3.5E−04
A_64_P092747 Mrvi1 NM_001105210 3.96 7.9E−06 2.7E−03
A_44_P1037953 Igf2 NM_031511 3.68 5.7E−08 1.4E−04
A_64_P093467 Trpc4 NM_080396 3.42 8.5E−07 7.4E−04
A_44_P1058692 Angpt1 NM_053546 3.41 3.0E-06 1.4E−03
A_64_P080817 Cd44 NM_012924 3.34 2.4E−06 1.2E−03
A_44_P577108 Rasgef1c NM_001108273 3.08 1.1E−07 2.0E−04
A_64_P082924 Rspo2 XM_006241608 3.07 7.4E−06 2.7E−03
A_44_P366723 Igf1 NM_178866 2.96 1.4E−06 9.3E−04
A_64_P053785 Adra2a NM_012739 2.89 1.0E−05 3.3E−03
The top 15 genes significantly induced by EPO at 20 h and unchanged by differentiation alone are listed. Cutoff for significance: fold change (FC) > 1.5 (log2 FC > 0.58) and BH adj. 
p-value < 0.05 in EPO-treated differentiated cells vs differentiation alone. Gene name of RGD1565355: similar to fatty acid/translocase/CD36.
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lipin 1 (Lpin1), Lpin2, Pnlip, peroxisome proliferator-activated 
receptor delta (Ppard), and perilipin 2 (Plin2). The effect of EPO 
on the expression of these genes in differentiating cells is reported 
in Table 3.
Validation of Microarray Data by qPcr
Microarray expression of eight genes of interest induced by EPO 
at 20 h, including the Igfs, Ptpre, some of the genes involved in 
lipid transport and metabolism and one myelin gene, Pmp2, 
was validated by RT-qPCR, using the same RNA used for the 
microarray experiment and RNA from a completely independent 
experiment (Figure 2). EPO-induced expression of all the eight 
genes tested was confirmed by RT-qPCR.
an inhibitor of erK Potentiates ePO-
induced Mog expression
To investigate whether EPO-induced PTPRE might contribute 
to the increased myelin gene expression, possibly by inhibiting 
ERK1/2 activation, we used an inhibitor of ERK1/2 phospho-
rylation, PD184352. In cells incubated with DM for 1 day, EPO 
increased the phosphorylation of ERK1/2, which peaked at 
10  min and returned to background level at 2  h (Figure  3A). 
Preincubation with PD184352 (0.1–2  µm) for 1  h completely 
inhibited EPO-induced ERK1/2 phosphorylation (Figure  3B), 
showing that the inhibitor was functionally active; PD184352 
also potentiated EPO-induced Mog expression (Figure 3C). This 
result showed that inhibition of the phosphorylation of ERK1/2, 
achieved by EPO by inducing PTPRE, might be a mechanism by 
which EPO increases myelin gene expression.
DiscUssiOn
The purpose of this study was to use gene expression profiling 
of CG4 OL cells to investigate the mechanism underlying the 
pro-myelinating action of EPO that we previously reported (8).
To this aim, we used CG4 cells transduced to overexpress 
EPOR. Evidence in the literature reports EPO effects on OLs, from 
cytoprotection to enhancement of differentiation and myelina-
tion, in vitro and in vivo (8, 10–13). EPOR is expressed in OLs in 
physiologic conditions, and its levels are increased by hypoxia, 
FigUre 2 | PCR validation of the microarray data. Results for eight genes at 20 h of erythropoietin (EPO) treatment are shown, comparing expression data from 
microarrays (left) with results from PCR analysis of the RNA from the same experiment (middle) and RNA from an independent experiment (right). Results for 
undifferentiated (white bars), differentiating (gray bars) and EPO-treated (black bars) differentiating samples are shown. Data are expressed as log2 fold change vs 
one of the respective undifferentiated samples and are the mean ± SD of four biological replicates. ***p < 0.001 vs differentiation alone; §p < 0.01 vs 
undifferentiated; #p < 0.001 undifferentiated by two-tailed Student’s t-test.
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injury, and chronic disease (43, 44), suggesting the involvement 
of the EPO–EPOR pathway in remyelination upon injury and 
disease of the CNS. The low availability of high numbers of pri-
mary OPCs makes it difficult to study the mechanisms mediating 
EPO pro-myelinating effects. To circumvent this problem, we 
used the CG4 cell line, a well-documented in vitro model of CNS 
myelination (17). However, as reported in our previous study, 
wild-type CG4 cells do not express EPOR; in cells transduced to 
express EPOR, EPO increased myelin gene expression, and we 
demonstrated, using clones with differential EPOR expression, 
that the response to EPO was increased as the level of EPOR 
increased, and was actually due to expression of EPOR and not 
to the vector itself (8).
In our in vitro system, we observed an inducing effect of EPO 
on genes previously known to play a role in myelination, such as 
Igf1, Igf2, and Ptpre, as well as genes involved in lipid transport 
and metabolism, including Fat/Cd36, Ppargc1a/Pgc1alpha, and 
Pnlip (18–24).
In general, the changes in gene expression profile induced by 
EPO identified two patterns.
For 43 transcripts, EPO amplified the effect of differentiation, 
augmenting their induction. These include three of the genes 
identified by DAVID in the functional groups “nervous system 
differentiation” and “cell adhesion” (Cdhr2, Mag, Ntm). In addi-
tion, Mag and Pnlip were reported as upregulated in primary rat 
OL compared with OPC (20, 34, 36, 45).
FigUre 3 | Inhibition of ERK1/2 phosphorylation potentiates erythropoietin 
(EPO)-induced Mog expression. (a) Time-course of EPO-induced 
phosphorylation of ERK1/2. (B) Dose–response of PD184352 on inhibition of 
ERK1/2 phosphorylation. (a,B) Cells were plated in GM for 24 h, then 
switched to DM and incubated overnight before treatment with medium 
alone or EPO at 10 ng/ml for the time indicated (a), or treated with DMSO or 
with different concentrations of PD184352 for 1 h and then with EPO 10 ng/
ml for 10 min. Phosphorylated ERK1/2 (upper bands) or total ERK1/2 as the 
loading control (lower bands) were analyzed by western blot. (c) PD184352 
increases EPO-induced Mog expression. Cells were plated in GM for 24 h, 
then switched to DM and treated with DMSO or PD184352 for 1 h and then 
with EPO at 10 ng/ml. Mog expression was measured by RT-qPCR at day 3. 
Data are the mean ± SD of four biological replicates and are representative of 
three independent experiments. ***p < 0.001 by two-tailed Student’s t-test.
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A second group of genes was represented by the 113 tran-
scripts upregulated by EPO and differentiation but not by dif-
ferentiation alone. These include a number of genes identified 
in previous studies to be expressed in primary myelinating OL 
[Acy3, Adamts4, Insc, Pdlim2, Prkcq (46, 47)], suggesting EPO 
may support OPC differentiation. This helps to explain the 
mechanism, at the gene expression level, of the pro-differentiat-
ing action of EPO on OLs described in other studies (10, 12, 13).
Among the genes whose expression was induced by DM and 
EPO but not by differentiation alone, the Igfs (Igf1 and Igf2) 
were among the top ones. IGF-1 effects on myelination in vivo 
and in vitro are well known (21, 48, 49). Of note, EPO-induced 
IGF-1 has been proposed as a mediator of EPO regenerative and 
remyelinating effects in the peripheral nervous system in rats 
(50). Therefore, IGF-1 might contribute to the effects of EPO in 
this system.
Both IGF-1 and IGF-2 are pro-myelinating cytokines, 
although the role of IGF-1 is better described (49). Interestingly, 
in the context of clinical samples, data in GEO3 (GSE38010) from 
Steinman’s group (51) show downregulation of Igf2 in chronic MS 
plaques compared to healthy controls whereas Igf1 expression did 
not change significantly.
Another gene among the top 15 induced by EPO was protein 
tyrosine phosphatase (PTP) receptor type E (Ptpre). Ranjan and 
Hudson found that PTP inhibitors decreased OL differentiation, 
and Ptpre, together with other PTP, was expressed in differentiat-
ing CG4 cells (18). Other PTPs have a role in OL maturation and 
myelination; Ptpa loss increased OPC proliferation (52); Ptprz 
knock out mice did not recover from EAE as well as controls and 
remyelination in MS plaques was associated with an upregula-
tion of PTPRZ (53); also, hypomyelination was observed in Ptpre 
knock out mice (19).
A link between PTPRE and OL differentiation might be 
provided by its ability to inhibit the ERK pathway (41). The role 
of ERK in myelination is controversial; overall ERK activation 
increases myelination, for instance increasing myelin thickness 
(54). However, ERK also mediates cell proliferation induced by 
growth factors that maintain the OPCs in an undifferentiated 
state, including PDGF (55); of note, PTPRE inhibits PDGF 
signaling (56). In this context, since we are focusing on the 
early events necessary to drive myelination during OPC to OL 
transition, it is likely that ERK activation needs to be inhibited 
to inhibit OPC proliferation and promote OL differentiation. 
EPO-induced ERK1/2 activation in these cells, detected only at 
10–60  min and then rapidly switched off, might be a negative 
feedback mechanism, not mediating but counteracting EPO-
induced myelination; in this regard, we have previously shown 
that inhibiting Egr2, downstream to ERK, Mog expression is 
increased (8). Therefore, EPO-induced PTPRE, by inhibiting the 
ERK pathway, might favor OL differentiation.
Another pathway that seems a major target of EPO in dif-
ferentiating OL is that of fatty acid transport and oxidation. Fat/
Cd36 was the second top induced gene. Of note, clinical data in 
GEO from Steinman’s group, mentioned above [see text footnote 
3; GSE38010 (51)] report downregulation of Cd36 in chronic 
MS plaques compared to healthy controls. The role of CD36 in 
mediating fatty acid uptake to enhance fatty acid oxidation has 
been described in muscle, heart, and adipose tissue (22, 42, 57); 
in macrophages, uptake of triacylglycerol-carrying lipoproteins 
via CD36 and lipolysis of triglycerides by lysosomal acid lipase 
increase oxidative phosphorylation of fatty acids and drive 
alternative (M2) macrophage activation (58). Together with 
Cd36, EPO increased the expression of Pnlip, recently shown to 
be expressed at high levels in differentiating OLs (20), possibly 
augmenting fatty acid uptake and utilization in OLs.
In addition, EPO-induced Ppargc1a/PGC-1alpha might 
mediate increased mitochondrial biogenesis; of note, EPO 
increases mitochondrial metabolism in heart and in muscle via 
PGC-1alpha (59, 60); moreover, both CD36 and PGC-1alpha can 
be induced via AMP kinase (AMPK) activation (61, 62), and EPO 
3 www.ncbi.nlm.nih.gov/geo.
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can activate AMPK in heart, in muscle and in white adipocytes 
(60, 63, 64). In the brain, EPO protection from ischemic damage 
is associated with preservation of Pgc1alpha expression (65); 
interestingly, PGC-1alpha is expressed in MBP-positive OL in the 
cerebellum and pharmacological upregulation of PGC-1alpha in 
OLs increased their differentiation, suggesting that PGC-1alpha 
has a role in CNS myelination (23, 66).
Altogether, increased expression of Cd36, Pnlip, Pgc1alpha, 
and other genes involved in lipid transport and metabolism 
(including Ldlr, not listed in Table 2 because inhibited by differ-
entiation alone) suggests that EPO can increase lipid utilization 
in these cells; fatty acids might then be used for myelin synthesis. 
In support of this, supplementation of OL with polyunsaturated 
fatty acids, and in particular with gamma-linoleic acid, can 
increase OL differentiation and myelin gene expression (67).
It is also tempting to speculate that EPO might have the abil-
ity to induce a metabolic shift toward oxidative phosphorylation 
fueled by fatty acid oxidation, described in macrophages as a 
driver of M2 polarization (58, 68, 69), which might favor the dif-
ferentiation of proliferating OPCs, mainly relying on aerobic gly-
colysis as a source of energy (38), into mature OLs. Although the 
brain mainly utilizes glucose as a source of energy, recent studies 
demonstrate that fatty acid oxidation can occur in neural and glial 
cells, including OLs (70–73). In addition, active mitochondrial 
metabolism has been recently described in mature OLs, previously 
thought to produce almost exclusively lactate to support neuron 
and axon survival (37, 74, 75). Interestingly, decreased oxidation 
of very long-chain fatty acids, reduced oxygen consumption 
and increased glycolysis have been described as mechanisms by 
which TNF inhibits OL differentiation (70, 76). Of note, dimethyl 
fumarate, a current effective therapy for recurrent MS, was found 
to increase oxidative metabolism and antioxidants levels and 
decrease the amount of lipids in OLs, suggesting that augmented 
lipid metabolism in OLs might mediate therapeutic effects in MS 
(77). It is interesting to note that PTPRE can also dephosphoryl-
ate insulin receptor (78), potentially inhibiting insulin signals and 
glucose utilization in these cells.
In conclusion, we have identified genes specifically induced 
by EPO in differentiating OLs which might contribute to the 
myelinating effects of EPO; while IGF-1 had been reported as 
a mediator of EPO’s myelinating effects in the peripheral nerv-
ous system, increased EPO-induced Igf1 and Igf2 expression in 
OLs had never been described. As for the EPO inducing effect 
on PTPRE, it is interesting to note that another phosphatase, 
dual-specificity protein phosphatase 5 (Dusp5), was among the 
few genes induced by EPO in rats with cerebral ischemia, where 
EPO treatment is protective (30). Of note, DUSP5 and PTPRE 
can downregulate the ERK pathway (41, 79). An effect of EPO 
FigUre 4 | Schematic of the possible molecular functions of lipid transport and metabolism genes induced by erythropoietin (EPO). Pnlip hydrolyzes triglycerides 
into fatty acids (20, 34); CD36 mediates transport of long-chain fatty acids and triacylglycerol-carrying low density lipoproteins (22, 42). Together with low density 
lipoprotein receptor (LDLR) and very low density LR (VLDLR), expressed in mature OLs (40), it might provide a source of fatty acids to increase fatty acid oxidation. 
Ppargc1a/PGC-1alpha, Lpin1, and Ppard increase mitochondrial biogenesis and fatty acid oxidation (24, 81–83). In mouse liver, Lpin1 can act as a transcriptional 
coactivator interacting with PGC-1alpha and peroxisome proliferator-activated receptor alpha (Ppara) (81). Lpin1 can also interact with Ppard, which might, 
therefore, be part of the coactivation complex (84). Fatty acid oxidation might provide acetyl CoA for myelin synthesis, or increase ATP production through the  
TCA cycle. In red the genes induced by EPO.
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